Johnson & Johnson subsidiary Janssen Pharmaceuticals has been ordered to pay $124 million to the state of South Carolina after the United States Supreme Court declined to hear an appeal by the company. The state of South Carolina filed a Risperdal lawsuit against the company, seeking civil penalties on two claims that alleged Janssen improperly marketed Risperdal and concealed its risks.
The Risperdal manufacturer was originally ordered to pay $327 million until the South Carolina Supreme Court reduced the amount to $124 million. Janssen was found to have included false information in a 2003 letter to the state’s prescribing physicians.
Janssen and J & J also face multiple Risperdal lawsuits alleging that the drug caused serious side effects, including breast tissue growth in boys and male adolescents. The drug makers have so far been ordered to pay millions of dollars to patients who received the antipsychotic and later developed breast tissue, a condition known as gynecomastia.